Halozyme Therapeutics Inc (HALO): Found this on Seeking Alpha: http://s...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Halozyme Therapeutics Inc (HALO)

Reply Private New

Keep Last Read

Replies (1) Next 10 Prev Next

Fred Kadiddlehopper

Send PM Follow Ignore

Followers	28
Posts	4448
Boards Moderated	1
Alias Born	09/22/2006

Fred Kadiddlehopper

Re: None

Monday, 02/13/2017 2:10:21 PM

Monday, February 13, 2017 2:10:21 PM

Found this on Seeking Alpha:

http://seekingalpha.com/news/3242834-mabvaxs-mvtminus-5873-shows-encouraging-action-preclinical-pancreatic-cancer-model-combined#email_link

MabVax's MVT-5873 shows encouraging action in preclinical pancreatic cancer model with combined with Halozyme's PEGPH20; shares ahead 6% premarket
Feb. 13, 2017 9:11 AM ET|About: MabVax Therapeutics Ho... (MBVX)|By: Douglas W. House, SA News Editor
Thinly traded nano cap MabVax Therapeutics Holdings (OTCQB:MBVX) is up 6% premarket on light volume in response to its announcement of positive results from a preclinical study assessing HuMab-5B1 antibody MVT-5873, combined with Halozyme Therapeutics' (NASDAQ:HALO) PEGPH20, in an animal model of pancreatic cancer. Results showed an improvement in accumulation of MVT-5873 on tumors when administered in sequence with PEGPH20.

MVT-5873 is currently in Phase 1 development to determine the recommended dose for Phase 2 studies.

PEGPH20 is an investigational drug administered intravenously that temporarily degrades hyaluronan, a chain of natural sugars that builds up around cancer cells inhibiting the effectiveness of cancer-killing therapies.

The more you know, the less you don't know.

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent HALO News

Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 10:49:57 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/18/2024 08:01:16 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/17/2024 08:03:48 PM
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis • PR Newswire (US) • 09/13/2024 05:30:00 PM
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer • PR Newswire (US) • 09/13/2024 12:00:00 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:56:59 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:12:07 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 08:05:49 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/10/2024 08:16:18 PM
Halozyme to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/28/2024 12:30:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 11:49:52 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:03:29 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2024 08:11:18 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 08:16:46 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:59:35 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 08:31:05 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:57:27 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 08:08:38 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 08:19:53 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:07:29 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:03:09 PM
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 08/06/2024 08:01:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:48:14 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/24/2024 08:05:48 PM

More HALO News

InvestorsHub NewsWire

VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM

Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM

HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM

Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM

Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM

PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow